REGENXBIO Inc. revenue by segment RGNX

Annual Quarterly

REGENXBIO Inc. splits its revenue into 12 lines in its filings. The largest line in fiscal 2025, which ended Dec 31, 2025 was Zolgensma Royalties at $82.5 million, 48% of the total.

USD in millions. The percent under a figure is the change from the year before.

Line	FY 2026 Sep 30, 2026	FY 2025 Dec 31, 2025	FY 2024 Dec 31, 2024	FY 2023 Dec 31, 2023	FY 2022 Dec 31, 2022	FY 2021 Dec 31, 2021	FY 2020 Dec 31, 2020	FY 2019 Dec 31, 2019	FY 2018 Dec 31, 2018	FY 2017 Dec 31, 2017	FY 2016 Dec 31, 2016
Revenue	154	170	83	90	113	470	155	35	219	10	5
Abb Vie Collaboration And License Agreement	—	—	—	—	—	370 share 78.7%	—	—	—	—	—
Zolgensma Royalties	—	83 +1.3% share 48.4%	82 -4.5% share 97.8%	85 -16.3% share 94.5%	102 +7.3% share 90.4%	95 +54.1% share 20.2%	62 +195.9% share 39.9%	21 share 59.1%	—	—	—
License And Service	—	—	82 -9.2% share 98.4%	90 -19.9% share 100.0%	113 -76.0% share 100.0%	470 +204.3% share 100.0%	155 +338.7% share 100.0%	35 -83.9% share 100.0%	219 +2004.0% share 100.0%	10 share 99.9%	—
Zolgensma And Itvisma Royalties	—	—	82 share 97.8%	—	—	—	—	—	—	—	—
Achievement Of Sales Based Milestone For Zolgensma	—	—	—	—	—	—	80 share 51.8%	—	—	—	—
Nippon Shinyaku Licenses	—	73 share 42.8%	—	—	—	—	—	—	—	—	—
Nippon Shinyaku Services	—	12 share 6.9%	—	—	—	—	—	—	—	—	—
Other Service Revenue	—	2 +71.9% share 1.4%	1 share 1.6%	—	—	—	—	—	—	—	—
Services	—	—	1 share 1.6%	—	—	—	—	—	—	—	—
Itvisma Royalties	—	1 share 0.4%	—	—	—	—	—	—	—	—	—
License	—	—	—	—	—	—	—	1 -99.7% share 1.7%	176 +16668.2% share 80.6%	1 share 10.1%	—
Product And Service Other	—	—	—	—	—	—	—	—	—	0 share 0.1%	—

How these figures are calculated

Annual columns are full-year amounts from the annual report (Form 10-K, 20-F, or 40-F). If a company restates a year, the latest filed number is shown. USD in millions. Each group is a separate split of total revenue, so the groups are not added together. Share of revenue is that line divided by total revenue. The first column adds the latest year-to-date segment amount to the last fiscal year and subtracts the year-ago year-to-date amount. More on our methodology.

Company profile

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836)
Listed as: RGNX (Nasdaq)
Fiscal year ends: December 31
Headquarters: Rockville, MD
SEC filer status: Non-accelerated filer, Smaller reporting company
SEC CIK: 1590877
Former names: ReGenX Biosciences, LLC (until Nov 7, 2013)

Other Biological Products, (No Diagnostic Substances) companies

All 182 Biological Products, (No Diagnostic Substances) companies

Source: SEC EDGAR filings. This is company-reported data, not investment advice.